PHILADELPHIA (Business Wire EON/PRWEB ) February 20, 2008 -- Xylos Corporation will present its biocellulose technology, clinical validations and business update to a combined group of venture capital firms and strategic partners at the In3 Medical Device Summit in Las Vegas (February 28, 2008 at 9:40am - Venetian Hotel). Mark S. McNulty, CEO, will provide an overview of the Company’s core biomaterial and describe its array of enabling technologies that allow Xylos to uniquely develop surgical implants designed to meet surgeon-defined performance and handling characteristics. Mr. McNulty explains, “The versatility of our biomaterial and our ability to bioengineer it to achieve the specific requirements needed by surgeons allows us to uniquely shift the paradigm for surgical implants. Our new class of biomaterial does not possess the shortfalls and limitations inherent in current materials from human, animal and petrochemical-based sources.”

Xylos is a medical device company that offers superior solutions for the treatment, repair and replacement of human tissue. The Company’s proprietary biocellulose technology possesses the effectiveness, versatility and safety profile to address a broad range of medical applications including surgical implants for musculoskeletal, urological / gynecological, general, abdominal, cardiovascular and plastic / aesthetics indications representing a market opportunity of over $4 billion. Additionally, Xylos’ biomaterial has unique drug delivery properties that have been demonstrated via in vitro and clinical evaluations. The Company has FDA cleared products and completed M&A transactions for select, discrete business units. The foundation of the Company and its success is based upon:

Using proprietary methods during and after biosynthesis, Xylos engineers its core biocellulose material to create surgical products that achieve precise surgeon-defined performance requirements and address shortfalls inherent in competitive devices. To protect the technology, Xylos controls, or has access to, more than 60 issued, pending and provisional patents worldwide, and also possess significant know-how and trade secrets. The Company has commercialized products internationally, achieved large scale manufacturing, has successful clinical trials experience, and obtained both U.S. and European regulatory clearances.

For further information, please visit www.xyloscorp.com or call 215-867-0220.

Home